Clinical trials: Platelet Inhibition
Acute Myocardial Infarction
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
The goal of this study is to find out how fast a drug called selatogrel (ACT-246475) can prevent platelets from binding together. This study will also help to find out more about the safety of this new drug.
- Trial name
- NCT03487445
- Testing
- Selatogrel 8 mg, Selatogrel 16 mg
- Where
- 6 sites in Belgium, Israel and 1 more
- Volunteers
- 48 people
- Sponsor
- Viatris Innovation GmbH
Coronary Artery Disease
COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT
This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and Outside United States (OUS).
- Trial name
- NCT01925794
- Testing
- COBRA PzF
- Where
- 35 sites in United States, France and 5 more
- Volunteers
- 296 people
- Sponsor
- CeloNova BioSciences, Inc.
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Diabetes Mellitus, Type 2, Coronary Artery Disease
Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in patients with DM who are known to have…
- Trial name
- OPTIMUS-6 (NCT03437044)
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
Coronary Artery Disease
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary…
- Trial name
- PRINCIPLE (NCT00357968)
- Testing
- Prasugrel, Clopidogrel
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 201 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Thrombocytopenia, Alloimmune Platelet Refractoriness
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Background: Platelets are tiny cells in the blood that help stop bleeding. Thrombocytopenia happens when people do not have enough normal platelets.
- Trial name
- NCT02298933
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myocardial Infarction, Arthritis
Mechanisms of Action of Acetaminophen
This research study investigates whether the ability of aspirin to reduce the risk of heart attacks may be diminished by the administration of acetaminophen.
- Trial name
- NCT00646906
- Testing
- Aspirin First, Aspirin Last, Acetaminophen 1000 mg/d
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Pharmacodynamics
Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products
The purpose of this study is to compare the pharmacodynamic effect of clopidogrel on the platelet inhibition and the pharmacokinetic profiles of clopidogrel carboxylic acid metabolite between generic and reference clopidogrel…
- Trial name
- NCT02010632
- Testing
- Generic clopidogrel product Apolets®, Original clopidogrel product Plavix®
- Where
- Thailand
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Khon Kaen University
Coronary Artery Disease
Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)
This research study plans to evaluate the use of atorvastatin in patients with coronary artery disease given immediately before PCI and whether it will decrease the amount of heart damage after PCI.
- Trial name
- ESTATE (NCT00979940)
- Testing
- Atorvastatin
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Indiana University
Ischemic Attack, Transient
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction.
- Trial name
- POINT (NCT00991029)
- Testing
- Clopidogrel
- Where
- 210 sites in United States, Australia and 8 more
- Volunteers
- 4,881 people
- Sponsor
- University of California, San Francisco
Acute Coronary Syndrome
A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
The study will compare the safety and efficacy of prasugrel, administered at different doses with clopidogrel in the treatment of Asian participants with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
- Trial name
- NCT00830960
- Testing
- Prasugrel, Clopidogrel
- Where
- 19 sites in China, South Korea and 2 more
- Volunteers
- 720 people
- Sponsor
- Eli Lilly and Company
Breast Neoplasms
A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients
The purpose of this study is to determine the effects of Plavix and aspirin in women with metastatic breast cancer.
- Trial name
- NCT00263211
- Testing
- Plavix, Aspirin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Systolic Heart Failure
Platelet Inhibition in Patients With Systolic Heart Failure
The investigators aim to determine if patients with systolic heart failure treated with prasugrel achieve greater platelet inhibition compared to those treated with clopidogrel.
- Trial name
- NCT01765400
- Testing
- Prasugrel 10 mg daily x 2 weeks, Clopidogrel 75 mg daily x 2 weeks
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Nebraska
Arterial Occlusive Diseases, Coronary Artery Disease
Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding.
- Conditions
- Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis
- Trial name
- TRIP-PCI (NCT02561000)
- Testing
- PZ-128
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tufts Medical Center
Platelet Inhibition, Coronary Stent Implantation
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode…
- Trial name
- IDEAL-PCI (NCT01515345)
- Testing
- prasugrel or ticagrelor, Clopidogrel
- Where
- Austria
- Volunteers
- 1,008 people
- Sponsor
- Kaiser Franz Josef Hospital
Diabetes Mellitus, Type 2
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as enteric…
- Trial name
- RITE (NCT02008942)
- Testing
- PL2200 Aspirin Capsules, Enteric-coated aspirin caplets
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- PLx Pharma
Atherosclerosis, Acute Coronary Syndrome (ACS)
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a…
- Trial name
- Platform (NCT00385138)
- Testing
- Cangrelor, clopidogrel
- Where
- United States
- Volunteers
- 5,364 people
- Sponsor
- The Medicines Company
ST-Segment Elevation Myocardial Infarction
Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction
To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
- Trial name
- NCT02075125
- Testing
- Prasugrel 60 mg, Ticagrelor 180 mg
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Dong-A University